Details for Patent: 9,550,759

Which drugs does patent 9,550,759 protect, and when does it expire?

Patent 9,550,759 protects ONGENTYS and is included in one NDA.

This patent has forty-one patent family members in twenty-seven countries.

Summary for Patent: 9,550,759

Patent landscape, scope, and claims:

Title:	Nitrocatechol derivatives as COMT inhibitors
Abstract:	New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
Inventor(s):	Learmonth; David Alexander (Valonga, PT), Kiss; Laszlo Erno (S. Mamede Do Coronado, PT), Palma; Pedro Nuno Leal (Leca de Palmeira, PT), Ferreira; Humberto Dos Santos (Maia, PT), Soares Da Silva; Patricio Manuel Vieira Araujo (Porto, PT)
Assignee:	BIAL--PORTELA & CA, S.A. (S. Mamede Do Coronado, PT)
Application Number:	14/541,654
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,550,759

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	9,550,759					ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY INCREASING L-DOPA AMOUNTS THAT REACH THE BRAIN
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	9,550,759					ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY INHIBITING COMT IN THE PERIPHERY
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	9,550,759					ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY REDUCING O-METHYLATION OF L-DOPA
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-002	Apr 24, 2020		RX	Yes	Yes	9,550,759					ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY INCREASING L-DOPA AMOUNTS THAT REACH THE BRAIN

Foreign Priority and PCT Information for Patent: 9,550,759

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0515327.5	Jul 26, 2005
	06008203	Apr 20, 2006
	06011073	May 30, 2006

International Family Members for US Patent 9,550,759

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1907382		300848	Netherlands
European Patent Office	1907382		122016000095	Germany
European Patent Office	1907382		PA2016036	Lithuania
European Patent Office	1907382		CA 2016 00061	Denmark